Company intelligence / Profile preview

AOA Dx

Ownership: Private
Development stage: Other

Overview

AOA Dx has developed GlycoLocate™, an AI-powered multi-omics diagnostic platform that leverages tumor marker gangliosides for early-stage ovarian cancer detection. Their lead product, AKRIVIS GD™, is a blood-based liquid biopsy currently undergoing clinical validation. The technology aims to provide high specificity and sensitivity for early diagnosis, addressing a critical unmet need in women’s health. Recent funding rounds are supporting further development and expansion of their pipeline.

Therapeutic areas: Oncology
Modalities: Diagnostic test (liquid biopsy)Multi-omics platformAI-enabled diagnostics
Industry: Protein Biomarker Diagnostics

Partnerships

McGill University

Beyond the preview

Go deeper on AOA Dx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AOA Dx.

Explore the full profile